Table 3.
Pathologic and oncologic outcomes
| Variables | Mean ± SD or n (%) |
|---|---|
| RP volume, cc | 44.2 ± 16.6 |
| Tumor volume, cc | 8.2 ± 8.9 |
| RP grade group | |
| 1 | 17 (2.7) |
| 2 | 215 (34.0) |
| 3 | 234 (37.0) |
| 4 | 48 (7.6) |
| 5 | 118 (18.7) |
| Pathologic ≥T3, n | 294 (46.5) |
| Presence of node metastasis, n | 22 (5.5) |
| Positive LNs, n | 0.12 ± 0.66 |
| Margin positivity, n | 191 (30.2) |
| Seminal vesicle invasion, n | 130 (20.6) |
| Bladder neck invasion, n | 45 (7.1) |
| Angiolymphatic invasion, n | 166 (26.1) |
| Perineural invasion, n | 545 (86.2) |
| Pad-free status, n | 470 (82.3) |
| ≤1 pad status, n | 511 (89.5) |
| BCR, n | 129 (20.3) |
| Cancer-specific mortality, n | 6 (0.9) |
| Overall mortality, n | 27 (4.3) |
Data are presented as mean ± SD and n (%).
BMI, body mass index; PSA, prostate-specific antigen; PIRADS, Prostate Imaging-Reporting and Data System; SD, standard deviation.